Fairmount Funds Management as of March 31, 2024
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 15 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 20.5 | $188M | 2.4M | 79.80 | |
| Nuvalent Inc-a (NUVL) | 15.8 | $145M | 1.9M | 75.09 | |
| Apogee Therapeutics (APGE) | 14.8 | $136M | 2.0M | 66.45 | |
| Dianthus Therapeutics (DNTH) | 9.0 | $83M | 2.8M | 30.00 | |
| Kiniksa Pharmaceuticals Com Cl A | 6.9 | $63M | 3.2M | 19.73 | |
| Enliven Therapeutics (ELVN) | 6.1 | $56M | 3.2M | 17.59 | |
| Astria Therapeutics (ATXS) | 5.5 | $50M | 3.6M | 14.07 | |
| Miragen Therapeutics (VRDN) | 3.5 | $32M | 1.8M | 17.51 | |
| Merus N V (MRUS) | 3.5 | $32M | 717k | 45.03 | |
| Cogent Biosciences (COGT) | 3.5 | $32M | 4.7M | 6.72 | |
| Protagonist Therapeutics (PTGX) | 2.9 | $27M | 932k | 28.93 | |
| Tyra Biosciences (TYRA) | 2.5 | $23M | 1.4M | 16.40 | |
| Geron Corporation (GERN) | 2.4 | $22M | 6.7M | 3.30 | |
| Spyre Therapeutics Com New (SYRE) | 1.6 | $14M | 378k | 37.93 | |
| Terns Pharmaceuticals (TERN) | 1.5 | $13M | 2.0M | 6.56 |
